Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jun 24, 2025; 16(6): 107255
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.107255
Efficacy of salvage surgery for hepatocellular carcinoma following conversion therapy
Shao-Bo Zhang, Bjorn Nashan, Yan-Li Wang, Shu-Geng Zhang
Shao-Bo Zhang, Bjorn Nashan, Shu-Geng Zhang, Department of Liver Transplantation, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Science and Medicine, University of Science and Technology of China, Hefei 230001, Anhui Province, China
Shao-Bo Zhang, Yan-Li Wang, Shu-Geng Zhang, Graduate School of Bengbu Medical University, Bengbu Medical University, Bengbu 233000, Anhui Province, China
Author contributions: Zhang SB and Zhang SG contributed to the conception and design of the study; Zhang SB and Wang YL contributed to acquisition of data; Zhang SB contributed to data analysis, administration or material support, drafted manuscript, and interpretation; Zhang SG verified the data; Nashan B and Zhang SG contributed to review and/or revision of the manuscript; and all authors have read and approved the final manuscript to be published.
Supported by the Anhui Provincial Department of Education, No. 2022AH020077.
Institutional review board statement: This study was approved by the Medical Ethics Committee of First Affiliated Hospital of the University of Science and Technology of China, Anhui Provincial Hospital, approval No. 2024-RE-186.
Informed consent statement: This is a retrospective study that confirms that the privacy and personal information of the patients involved is confidential and, therefore, informed consent is not required for this study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated and analyzed during the present study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Geng Zhang, Department of Liver Transplantation, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Science and Medicine, University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei 230001, Anhui Province, China. zsg0517@ustc.edu.cn
Received: March 19, 2025
Revised: April 15, 2025
Accepted: May 7, 2025
Published online: June 24, 2025
Processing time: 93 Days and 9.9 Hours
Core Tip

Core Tip: For patients with advanced hepatocellular carcinoma, the opportunity for radical surgical treatment is lost. Patients who receive targeted drugs, immune drugs, or localized regional therapies cannot achieve a complete cure in the clinical sense, although it may lead to remission of the tumor lesions and improve overall survival. Patients after receiving transcatheter arterial chemoembolization combined with targeted and immune drugs, the liver cancer lesions were in remission, which was in line with the indication range of surgical resection. Postoperative complications in patients treated with salvage surgery were within acceptable limits and overall survival was prolonged.